Opinion on R&D in Europe

Published within

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

HRT: no new prescriptions

After the Prempro arm of the Women's Health Initiative trial was stopped last week, the UK's Department of Health in the UK said that no new prescriptions should be made for HRT as a preventative treatment for cardiovascular disease. The decision will hit the use of HRT in the UK, potentially driving uptake of Eli Lilly's Evista.

Published By Datamonitor
15 Jul 2002
CommentWire
CommentWire

Herpes: infra-red light may cure cold sores

The new device could prove a more efficacious therapy than currently marketed drugs, creating a threat to sales of GSK and Novartis' market leading drugs. However, it is unlikely to take off if patients have to get a doctors' appointment to use it. Home self-treatment kits will be required for market success.

Published By Datamonitor
09 Apr 2002
CommentWire
CommentWire

Hepatitis A vaccine: more protection than expected

A new study suggests the hepatitis A vaccine may provide immunity for over 20 years. A new Swiss study predicts that two doses of the hepatitis A vaccine will provide immunity for over 20 years. This is longer than previously thought.<BR />

Published By Datamonitor
13 Dec 2002
CommentWire
CommentWire

Heinz: beans beat broccoli (sometimes)

The British Dietetic Association found that several of Heinz' canned foods help consumers to consume five portions of fruit and vegetables per day. But although Heinz is set to capitalize on the research, rebranding dozens of its products to emphasize the health benefits, it may keep some of the BDA's other findings away from its labels.

Published By Datamonitor
18 Apr 2002
CommentWire
CommentWire

GW Pharma: more cannabis spray trials

GW is in a unique position. Although cannabis use is illegal in the UK, the company has the right to grow the drug for use in clinical trials. If the latest trials are successful, up to 40% of cancer patients may be able to benefit from the therapy. Strong trial results would leave GW in a position to gain approval for its product as early as 2004.

Published By Datamonitor
21 Jan 2002
CommentWire
CommentWire

GSK: short term bright, long term gloomy

GSK is expected to launch a number of new drugs and indications in the short to medium-term, following a series of FDA approvals. However, negative factors such as generic risk will prevent strong growth going forward. GSK needs to consider a more aggressive strategy to boost future prospects.<BR /><BR /><BR />

Published By Datamonitor
19 Dec 2002
CommentWire
CommentWire

GSK: more marketing synergies and less R&D trouble

GSK currently has one of the industry's strongest salesforces, but a relatively weak late-stage pipeline. As well as signing several in-licensing and co-marketing deals with companies including Bayer and Roche, the pharma giant is also considering spinning off some of its R&D activities. This could well be the best route to continued double-digit growth.

Published By Datamonitor
21 Feb 2002
CommentWire
CommentWire

GSK: looking further ahead with Exelixis deal

GSK's partnership with genomics-based drug discovery firm Exelexis is a logical move. The pharma giant has already bolstered its weak late stage pipeline with licensing deals; Exelixis should help do the same for its early stage pipeline. GSK is successfully using its vast financial resources to compensate for the failure of its internal R&D.

Published By Datamonitor
30 Oct 2002
CommentWire
CommentWire

GSK: antidepressant leader under threat

The Chicago court ruling will see Apotex's Paxil generic impact the GSK bi-blockbuster antidepressant from 2005. Moreover, GSK's follow up antidepressant, vilazadone, appears to be struggling to proceed to market, leaving GSK with a wealth of depression expertise but a foreseeable dent in its antidepressant revenue stream.

Published By Datamonitor
07 Mar 2003
CommentWire
CommentWire

GSK/Bayer: vardenafil closer to challenging Viagra

Pfizer's Viagra has monopolized the erectile dysfunction market, but will face competition from GSK/Bayer's vardenafil and Lilly's Cialis when these drugs launch in 2003. Whether the challengers will take substantial market share from Viagra, however, depends on whether GSK and Lilly can persuade physicians and consumers that they offer significant advantages.

Published By Datamonitor
26 Jul 2002

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | » »|

No help is available.